Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Cardiol ; 47(1): e24183, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37933175

RESUMO

AIM: This study aims to characterize sociodemographic and clinical characteristics, use of lipid-lowering therapies (LLTs), and low-density lipoprotein cholesterol (LDL-C) control in a population with increased cardiovascular (CV) risk. METHODS: A cross-sectional observational study that uses electronic health records of patients from one hospital and across 14 primary care health centers in the North of Portugal, spanning from 2000 to 2020 (index date). Patients presented at least (i) 1 year of clinical data before inclusion, (ii) one primary care appointment 3 years before the index date, and (iii) sufficient data for CV risk classification. Patients were divided into three cohorts: high CV risk; atherosclerotic cardiovascular disease (ASCVD) risk equivalents without established ASCVD; evidence of ASCVD. CV risk and LDL-C control were defined by the 2019 and 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidemia guidelines. RESULTS: A total of 51 609 patients were included, with 23 457 patients classified as high CV risk, 19 864 with ASCVD equivalents, and 8288 with evidence of ASCVD. LDL-C control with 2016 ESC/EAS guidelines was 32%, 10%, and 18% for each group, respectively. Considering the ESC/EAS 2019 guidelines control level was even lower: 7%, 3%, and 7% for the same cohorts, respectively. Patients without any LLT prescribed ranged from 37% in the high CV risk group to 15% in patients with evidence of ASCVD. CONCLUSION: We found that LDL-C control was very low in patients at higher risk of CV events. An alarming gap between guidelines on dyslipidemia management and clinical implementation persists, even in those at very high risk or with established ASCVD.


Assuntos
Aterosclerose , Doenças Cardiovasculares , Dislipidemias , Inibidores de Hidroximetilglutaril-CoA Redutases , Humanos , LDL-Colesterol , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Estudos Transversais , Fatores de Risco , Dislipidemias/diagnóstico , Dislipidemias/tratamento farmacológico , Dislipidemias/epidemiologia , Aterosclerose/epidemiologia , Aterosclerose/tratamento farmacológico , Fatores de Risco de Doenças Cardíacas
2.
Atherosclerosis ; 384: 117148, 2023 11.
Artigo em Inglês | MEDLINE | ID: mdl-37302923

RESUMO

BACKGROUND AND AIMS: Cardiovascular (CV) diseases show clear differences in clinical manifestation and treatment outcomes between men and women. To reduce sex disparities in achieving lipid-lowering therapy (LLT) goals, a sex-focused assessment is essential and more studies are needed to bring new evidence to clinicians. This study aims to assess the role of sex in attaining low-density lipoprotein cholesterol (LDL-C) goals, after correction for age, CV risk category, LLT intensity, and presence of mental health disorder and social deprivation. METHODS: A retrospective cohort analysis of patients aged 40-85, followed in 1 hospital and 14 primary care centers in Portugal, using electronic health records from 1/1/2012 to 31/12/2020, was performed. The analysis considered an episode-based design, where exposure consists of any time when LLT was started or intensity changed. The likelihood of reaching the LDL-C goal according to contemporary ESC/EAS guidelines was modeled using multivariate Cox regression. LDL-C goal achievement at 180 days was defined as the outcome. The analysis was repeated at 30-day follow-up intervals up to 360 days, and also stratified by CV risk category. RESULTS: We identified 40,032 exposure episodes (LLT initiation or intensity change) in 30,323 distinct patients. Male sex, older age, lower CV risk and increasing LLT intensity were associated with improved LDL-C control. Women were 22% less likely to reach the LDL-C goal than men (HR = 0.78, 95% CI:0.73, 0.82) independently of covariates. CONCLUSIONS: Women have a lower likelihood of attaining LDL-C goals than men after adjustment for LLT intensity, age, CV risk category, presence of mental health disorder and social deprivation. This finding underscores the need for further investigation and tailoring of LLT management strategies in women.


Assuntos
Doenças Cardiovasculares , Inibidores de Hidroximetilglutaril-CoA Redutases , Humanos , Masculino , Feminino , LDL-Colesterol , Estudos Retrospectivos , Caracteres Sexuais , Estudos de Coortes , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Atenção Primária à Saúde , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
3.
J Cardiopulm Rehabil Prev ; 34(1): 2-20, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24370759

RESUMO

INTRODUCTION: The newer generation of active video games (AVGs), which allow the participant to interact with the platform by performing exercise movements, seems promising in increasing physical activity (PA) and behavioral change toward a healthier lifestyle in several disease backgrounds. This literature review aims to establish a rationale for using AVGs as a complement to cardiac rehabilitation (CR). METHODS: A systematic review was conducted to query whether AVGs are effective at improving various health parameters in adults/seniors, which could be useful for CR. From 134 identified studies, only 21 were finally included as trials meeting the required criteria. The majority reported gameplay intensities that could be classified as light-moderate PA. AVGs revealed superior effectiveness or noninferiority at improving balance. DISCUSSION: AVGs seem to offer numerous relevant cardiovascular and noncardiovascular benefits and pose minimal risks for the adult/senior population. AVGs seem a feasible, effective, and safe supplementation strategy, in light of the specificities of the CR population. Clinicians could borrow several concepts incorporated in AVGs to develop a CR intervention that is fun and engaging to improve adherence. CONCLUSION: On the basis of this review, the usefulness of AVGs to improve PA, cardiorespiratory fitness, and motor function in older adults appears to be poorly described. In particular, data on the impact of AVGs on the CR population seem inexistent. Nevertheless, there are reasons to believe that AVGs may prove important to address the health and well-being concerns of this population. More research in the specific setting of CR is warranted.


Assuntos
Cardiopatias/reabilitação , Aptidão Física , Jogos de Vídeo , Adulto , Atitude Frente a Saúde , Cardiopatias/psicologia , Humanos , Relações Interpessoais , Atividade Motora , Aptidão Física/fisiologia , Aptidão Física/psicologia
4.
Rev Port Cardiol ; 31(2): 151-8, 2012 Feb.
Artigo em Português | MEDLINE | ID: mdl-22237005

RESUMO

Levels of physical activity in modern urbanized society are clearly insufficient to maintain good health, and to prevent cardiovascular and other disease. Aerobic exercise is almost completely free of secondary effects, and is a useful adjunctive therapy in treating hypertension. There are several possible mechanisms to account for the beneficial effects of exercise in reducing blood pressure, the resulting physiological effects usually being classified as acute, post-exercise or chronic. Variations in genetic background, hypertension etiology, pharmacodynamics and pharmacokinetics may explain the different blood pressure responses to exercise among hypertensive patients. The present review discusses the different pathophysiological aspects of the response to exercise in hypertensives, including its modulators and diagnostic and prognostic usefulness, as well as the latest guidelines on prescribing and monitoring exercise regimes and drug therapy in the clinical follow-up of active hypertensive patients.


Assuntos
Terapia por Exercício , Hipertensão/terapia , Humanos , Hipertensão/fisiopatologia , Monitorização Fisiológica , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA